101 related articles for article (PubMed ID: 23973746)
1. Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis.
Braidy N; Lim CK; Grant R; Brew BJ; Guillemin GJ
Brain Res; 2013 Nov; 1537():267-72. PubMed ID: 23973746
[TBL] [Abstract][Full Text] [Related]
2. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.
Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M
J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961
[TBL] [Abstract][Full Text] [Related]
3. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
5. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes.
Jalonen TO; Pulkkinen K; Ukkonen M; Saarela M; Elovaara I
J Neurol; 2002 May; 249(5):576-83. PubMed ID: 12021948
[TBL] [Abstract][Full Text] [Related]
6. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
[TBL] [Abstract][Full Text] [Related]
7. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
8. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.
Ramsaransing GS; Heersema DJ; De Keyser J
Eur J Neurol; 2005 Jul; 12(7):514-8. PubMed ID: 15958090
[TBL] [Abstract][Full Text] [Related]
9. Plasma S100beta and NSE levels and progression in multiple sclerosis.
Koch M; Mostert J; Heersema D; Teelken A; De Keyser J
J Neurol Sci; 2007 Jan; 252(2):154-8. PubMed ID: 17187827
[TBL] [Abstract][Full Text] [Related]
10. Serum NSE level and disability progression in multiple sclerosis.
Koch MW; George S; Wall W; Wee Yong V; Metz LM
J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
12. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
14. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
[TBL] [Abstract][Full Text] [Related]
15. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
16. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis.
Villar LM; Masterman T; Casanova B; Gómez-Rial J; Espiño M; Sádaba MC; González-Porqué P; Coret F; Alvarez-Cermeño JC
J Neuroimmunol; 2009 Jun; 211(1-2):101-4. PubMed ID: 19443047
[TBL] [Abstract][Full Text] [Related]
17. NMR-based metabolomics identification of potential serum biomarkers of disease progression in patients with multiple sclerosis.
Alwahsh M; Nimer RM; Dahabiyeh LA; Hamadneh L; Hasan A; Alejel R; Hergenröder R
Sci Rep; 2024 Jun; 14(1):14806. PubMed ID: 38926483
[TBL] [Abstract][Full Text] [Related]
18. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
[TBL] [Abstract][Full Text] [Related]
19. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
